These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 2124097)
21. Liver involvement in human schistosomiasis mansoni. Assessment by immunological and biochemical markers. Zwingenberger K; Feldmeier H; Queiroz JA; Siqueira JG; Auto HF; Alencar JE; Bienzle U Parasitol Res; 1988; 74(5):448-55. PubMed ID: 3137558 [TBL] [Abstract][Full Text] [Related]
22. Possible antifibrotic effect of GDC-0449 (Vismodegib), a hedgehog-pathway inhibitor, in mice model of Schistosoma-induced liver fibrosis. Elhenawy AA; Ashour RH; Nabih N; Shalaby NM; Megahed N Parasitol Int; 2017 Oct; 66(5):545-554. PubMed ID: 28408356 [TBL] [Abstract][Full Text] [Related]
23. Ultrasonographical investigation of periportal fibrosis in children with Schistosoma mansoni infection: reversibility of morbidity twenty-three months after treatment with praziquantel. Doehring-Schwerdtfeger E; Abdel-Rahim IM; Kardorff R; Kaiser C; Franke D; Schlake J; Richter J; Elsheikh M; Mohamed-Ali Q; Ehrich JH Am J Trop Med Hyg; 1992 Apr; 46(4):409-15. PubMed ID: 1575287 [TBL] [Abstract][Full Text] [Related]
24. Praziquantel for treatment of schistosomiasis in patients with advanced hepatosplenomegaly. Bassily S; Farid Z; Dunn M; el-Masry NA; Stek M Ann Trop Med Parasitol; 1985 Dec; 79(6):629-34. PubMed ID: 3938936 [TBL] [Abstract][Full Text] [Related]
25. Reversibility of Schistosoma mansoni-associated morbidity after yearly mass praziquantel therapy: ultrasonographic assessment. Boisier P; Ramarokoto CE; Ravaoalimalala VE; Rabarijaona L; Serieye J; Roux J; Esterre P Trans R Soc Trop Med Hyg; 1998; 92(4):451-3. PubMed ID: 9850407 [TBL] [Abstract][Full Text] [Related]
26. Evidence for a long-term effect of a single dose of praziquantel on Schistosoma mansoni-induced hepatosplenic lesions in northern Uganda. Frenzel K; Grigull L; Odongo-Aginya E; Ndugwa CM; Loroni-Lakwo T; Schweigmann U; Vester U; Spannbrucker N; Doehring E Am J Trop Med Hyg; 1999 Jun; 60(6):927-31. PubMed ID: 10403322 [TBL] [Abstract][Full Text] [Related]
27. Circulating schistosomal antigen in diagnosis and assessment of cure in individuals infected with Schistosoma mansoni. Hassan MM; Badawi MA; Strand M Am J Trop Med Hyg; 1992 Jun; 46(6):737-44. PubMed ID: 1621899 [TBL] [Abstract][Full Text] [Related]
28. Praziquantel and oltipraz: the treatment of schoolchildren infected with Schistosoma mansoni and/or Schistosoma haematobium in Gezira, Sudan. el Tayeb M; Daffalla AA; Kardaman MW; See R; Fenwick A Ann Trop Med Parasitol; 1988 Feb; 82(1):53-7. PubMed ID: 3135786 [TBL] [Abstract][Full Text] [Related]
29. Sequential analysis of helminth egg output in human stool samples following albendazole and praziquantel administration. Scherrer AU; Sjöberg MK; Allangba A; Traoré M; Lohourignon LK; Tschannen AB; N'Goran EK; Utzinger J Acta Trop; 2009 Mar; 109(3):226-31. PubMed ID: 19070583 [TBL] [Abstract][Full Text] [Related]
30. Assessment of cure in schistosomiasis patients after chemotherapy with praziquantel by quantitation of circulating anodic antigen (CAA) in urine. van Lieshout L; de Jonge N; Bassily S; Mansour MM; Deelder AM Am J Trop Med Hyg; 1991 Mar; 44(3):323-8. PubMed ID: 1903605 [TBL] [Abstract][Full Text] [Related]
31. Serological analysis of the outcome of treatment of Schistosoma mansoni infections with praziquantel. Bligh J; Schramm G; Chiodini PL; Doenhoff MJ Ann Trop Med Parasitol; 2010 Sep; 104(6):511-20. PubMed ID: 20863440 [TBL] [Abstract][Full Text] [Related]
32. The effect of praziquantel against Schistosoma mansoni-infections in Botswana. Friis H; Byskov J Trop Geogr Med; 1989 Jan; 41(1):49-51. PubMed ID: 2503911 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of the patterns of Schistosoma mansoni infection and re-infection in Senegal, from faecal egg counts and serum concentrations of circulating anodic antigen. Polman K; Stelma FF; Le Cessie S; De Vlas SJ; Falcão Ferreira ST; Talla I; Deelder AM; Gryseels B Ann Trop Med Parasitol; 2002 Oct; 96(7):679-89. PubMed ID: 12537629 [TBL] [Abstract][Full Text] [Related]
34. Immunity after treatment of human schistosomiasis mansoni. III. Long-term effects of treatment and retreatment. Sturrock RF; Bensted-Smith R; Butterworth AE; Dalton PR; Kariuki HC; Koech D; Mugambi M; Ouma JH; arap Siongok TK Trans R Soc Trop Med Hyg; 1987; 81(2):303-14. PubMed ID: 3113005 [TBL] [Abstract][Full Text] [Related]
35. Rapid clearance of Schistosoma mansoni circulating cathodic antigen after treatment shown by urine strip tests in a Ugandan fishing community - Relevance for monitoring treatment efficacy and re-infection. Kildemoes AO; Vennervald BJ; Tukahebwa EM; Kabatereine NB; Magnussen P; de Dood CJ; Deelder AM; Wilson S; van Dam GJ PLoS Negl Trop Dis; 2017 Nov; 11(11):e0006054. PubMed ID: 29131820 [TBL] [Abstract][Full Text] [Related]
36. Altered generation of interleukin 1 in chronic human schistosomiasis mansoni. Zwingenberger K; Richter J; Taupitz S; Vergetti Siqueira JG; Correia Dacal AR Scand J Immunol; 1990 Jun; 31(6):729-36. PubMed ID: 2113308 [TBL] [Abstract][Full Text] [Related]
37. Praziquantel efficacy against schistosomiasis mansoni in schoolchildren in north-west Ethiopia. Degu G; Mengistu G; Jones J Trans R Soc Trop Med Hyg; 2002; 96(4):444-5. PubMed ID: 12497985 [TBL] [Abstract][Full Text] [Related]
38. Treatment of Schistosoma mansoni infection increases helminth-specific type 2 cytokine responses and HIV-1 loads in coinfected Ugandan adults. Brown M; Mawa PA; Joseph S; Bukusuba J; Watera C; Whitworth JA; Dunne DW; Elliott AM J Infect Dis; 2005 May; 191(10):1648-57. PubMed ID: 15838791 [TBL] [Abstract][Full Text] [Related]
39. Association of the therapeutic activity of praziquantel with the reversal of Symmers' fibrosis induced by Schistosoma mansoni. Homeida MA; el Tom I; Nash T; Bennett JL Am J Trop Med Hyg; 1991 Sep; 45(3):360-5. PubMed ID: 1928571 [TBL] [Abstract][Full Text] [Related]
40. Effects of single-dose praziquantel on morbidity and mortality resulting from intestinal schistosomiasis. Kheir MM; Baraka OZ; el-Tom IA; Mukhtar MM; Homieda MM East Mediterr Health J; 2000; 6(5-6):926-31. PubMed ID: 12197350 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]